After ASO optimization, we evaluated targeted delivery to 22Rv1 PSMA-positive prostate cancer cells using two previously published PSMA ligands–a common Glu-Lys urea-based peptidomimetic MA-415, and an advanced version with improved binding to the receptor MA-257 (Supplementary Figure S2) (Machulkin et al., 2019; Machulkin et al., 2021). This evidence concerns the gene FOLH1 and prostate carcinoma.